Page 56 - Read Online

Sooi et al. Cancer Drug Resist 2023;6:656-73 https://dx.doi.org/10.20517/cdr.2023.48 Page 672

98. Galluzzi L, Buqué A, Kepp O, Zitvogel L, Kroemer G. Immunological effects of conventional chemotherapy and targeted anticancer
agents. Cancer Cell 2015;28:690-714. DOI PubMed
99. Dosset M, Vargas TR, Lagrange A, et al. PD-1/PD-L1 pathway: an adaptive immune resistance mechanism to immunogenic
chemotherapy in colorectal cancer. Oncoimmunology 2018;7:e1433981. DOI PubMed PMC
100. Alizadeh D, Trad M, Hanke NT, et al. Doxorubicin eliminates myeloid-derived suppressor cells and enhances the efficacy of adoptive
T-cell transfer in breast cancer. Cancer Res 2014;74:104-18. DOI PubMed PMC
101. Vicari AP, Luu R, Zhang N, et al. Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor
effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother 2009;58:615-28. DOI PubMed
102. Garnett CT, Schlom J, Hodge JW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor
activity: effects of docetaxel on immune enhancement. Clin Cancer Res 2008;14:3536-44. DOI PubMed PMC
103. Fizazi K, Gonzalez Mella P, Castellano D, et al. Efficacy and safety of nivolumab in combination with docetaxel in men with
metastatic castration-resistant prostate cancer in CheckMate 9KD. Ann Oncol 2019;30:v885-6. DOI
104. Sridhar SS, Kolinsky MP, Gravis G, et al. Pembrolizumab (pembro) plus docetaxel and prednisone in patients (pts) with abiraterone
acetate (abi) or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B
efficacy, safety and, biomarker results. J Clin Oncol 2020;38:5550. DOI
105. Sartor O, de Bono J, Chi KN, et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N Engl J Med
2021;385:1091-103. DOI PubMed PMC
106. Chen H, Zhao L, Fu K, et al. Integrin α β -targeted radionuclide therapy combined with immune checkpoint blockade immunotherapy
v 3
synergistically enhances anti-tumor efficacy. Theranostics 2019;9:7948-60. DOI PubMed PMC
107. Morris MJ, Fong L, Petrylak DP, et al. Safety and clinical activity of atezolizumab (atezo) + radium-223 dichloride (r-223) in 2L
metastatic castration-resistant prostate cancer (mCRPC): results from a phase Ib clinical trial. J Clin Oncol 2020;38:5565. DOI
177
108. Sandhu SK, Joshua AM, Emmett L, et al. 577O PRINCE: interim analysis of the phase Ib study of Lu-PSMA-617 in combination
with pembrolizumab for metastatic castration resistant prostate cancer (mCRPC). Ann Oncol 2021;32:S626-7. DOI
109. Fu J, Shang Y, Qian Z, et al. Chimeric Antigen receptor-T (CAR-T) cells targeting Epithelial cell adhesion molecule (EpCAM) can
inhibit tumor growth in ovarian cancer mouse model. J Vet Med Sci 2021;83:241-7. DOI PubMed PMC
110. Narayan V, Barber-Rotenberg JS, Jung IY, et al. PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-
resistant prostate cancer: a phase 1 trial. Nat Med 2022;28:724-34. DOI PubMed PMC
111. Slovin SF, Dorff TB, Falchook GS, et al. Phase 1 study of P-PSMA-101 CAR-T cells in patients with metastatic castration-resistant
prostate cancer (mCRPC). J Clin Oncol 2022;40:98. DOI
112. Bębnowska D, Grywalska E, Niedźwiedzka-Rystwej P, et al. CAR-T cell therapy - an overview of targets in gastric cancer. J Clin Med
2020;9:1894. DOI PubMed PMC
113. He C, Zhou Y, Li Z, et al. Co-expression of IL-7 improves NKG2D-based CAR T cell therapy on prostate cancer by enhancing the
expansion and inhibiting the apoptosis and exhaustion. Cancers 2020;12:1969. DOI PubMed PMC
114. Yang S, Wei W, Zhao Q. B7-H3, a checkpoint molecule, as a target for cancer immunotherapy. Int J Biol Sci 2020;16:1767-73. DOI
PubMed PMC
115. Hummel HD, Kufer P, Grüllich C, et al. Phase I study of pasotuxizumab (AMG 212/BAY 2010112), a PSMA-targeting BiTE
(Bispecific T-cell Engager) immune therapy for metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 2020;38:124.
DOI
116. Tran B, Horvath L, Dorff T, et al. 609O results from a phase I study of AMG 160, a half-life extended (HLE), PSMA-targeted,
bispecific T-cell engager (BiTE®) immune therapy for metastatic castration-resistant prostate cancer (mCRPC). Ann Oncol
2020;31:S507. DOI
117. Lin TY, Park JA, Long A, Guo HF, Cheung NV. Novel potent anti-STEAP1 bispecific antibody to redirect T cells for cancer
immunotherapy. J Immunother Cancer 2021;9:e003114. DOI PubMed PMC
118. Dorff TB, Narayan V, Forman SJ, et al. Novel redirected T-cell immunotherapies for advanced prostate cancer. Clin Cancer Res
2022;28:576-84. DOI PubMed PMC
119. Vijayan D, Young A, Teng MWL, Smyth MJ. Targeting immunosuppressive adenosine in cancer. Nat Rev Cancer 2017;17:709-24.
DOI PubMed
120. Schmiel SE, Yang JA, Jenkins MK, Mueller DL. Cutting edge: adenosine A2a receptor signals inhibit germinal center T follicular
helper cell differentiation during the primary response to vaccination. J Immunol 2017;198:623-8. DOI PubMed PMC
+ 1
121. Lappas CM, Rieger JM, Linden J. A adenosine receptor induction inhibits IFN-γ production in murine CD4 T cells . J Immunol
2A
2005;174:1073-80. DOI PubMed
122. Ha H, Debnath B, Neamati N. Role of the CXCL8-CXCR1/2 axis in cancer and inflammatory diseases. Theranostics 2017;7:1543-88.
DOI PubMed PMC
123. Yuen KC, Liu LF, Gupta V, et al. High systemic and tumor-associated IL-8 correlates with reduced clinical benefit of PD-L1
blockade. Nat Med 2020;26:693-8. DOI PubMed PMC
124. Calcinotto A, Spataro C, Zagato E, et al. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. Nature
2018;559:363-9. DOI PubMed PMC
125. Shorning BY, Dass MS, Smalley MJ, Pearson HB. The PI3K-AKT-mTOR pathway and prostate cancer: at the crossroads of AR,
MAPK, and WNT signaling. Int J Mol Sci 2020;21:4507. DOI PubMed PMC